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A 26-year-old woman of Vietnamese descent
presented to the emergency department with a
widespread, symmetric, erythematous, and pustular
eruption (Fig 1). The outbreak initially affected the
waistline, and the axillary, inguinal, and inframam-
mary folds. It then spread to involve the neck,
wrists, areolae, and the antecubital and popliteal
fossae (Fig 2). The pustules were superficial, flaccid,
and nonfollicular. They quickly evolved to become
confluent, forming purulent lakes (Fig 1).
There was sparing of the lower aspect of the
legs, palms, soles, and upper aspect of back.
Nikolsky sign and mucous membrane involvement
were absent. There were no target lesions or
blisters. In addition, she experienced a diffuse
burning sensation, facial swelling, subjective fe-
vers, and malaise.
The patient had consumed 10 mg of mifepristone
as emergency contraception 2 days before the
eruption. She had not taken any other medications
before her eruption and was not previously ill. The
mifepristone was purchased without a prescription
at a pharmacy in Vietnam. She reported using the
medication once prior in a similar circumstance
without incident.
On presentation, the patient was tachycardic
(heart rate: 150 beats/min) with an elevated
temperature (37.78C). Laboratory studies demon-
strated notable abnormalities of total lymphocyte
count 18,000/mm3 (3500-10,500/mm3), absolute
neutrophils 17,800/mm3 (1700-7000/mm3), albumin
2.3 g/dL (3.5-5.0 g/dL), calcium 6.5 mg/dL
(8.9-10.1 mg/dL), alkaline phosphatase 31 U/L
(37-98 U/L), sodium 131 mmol/L (135-145 mmol/L),the Department of Dermatology at Mayo Clinic.
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Case Reports 2015;1:191-5.potassium 3.2 mmol/L (3.6-5.2 mmol/L), bicarbon-
ate 19 mmol/L (22-29 mmol/L), phosphorus
1.8 mg/dL (2.5-4.5 mg/dL), and glucose 179 mg/
dL (70-100 mg/dL). The remainder of the renal
and liver function tests revealed unremarkable
findings.
Skin swab cultures and blood cultures for bacte-
ria, and skin swab polymerase chain reaction for
varicella zoster virus and herpes simplex virus were
negative. The quantitative human chorionic gonad-
otropin was 1982.0 mIU/mL, and the patient’s last
reported menstrual period was approximately
5 weeks prior. She was unaware of her pregnancy.
Before the human chorionic gonadotropin result,
the patient was treated with 125 mg of methylpred-
nisolone and 1 g of ceftriaxone in the emergency
department. She was then admitted to the hospital
and received a second 125-mg dose of methylpred-
nisolone, and four 600-mg doses of clindamycin as a
hospital inpatient, before dermatologic
consultation.
Punch biopsy specimen demonstrated extensive
subcorneal pustules with neutrophil spongiosis,
prominent papillary dermal edema with hemor-
rhage, and a brisk perivascular mixed inflammatory
infiltrate with many neutrophils and eosinophils
(Fig 3). Focal small-vessel vasculitis was present
(Fig 4).
A diagnosis of acute generalized exanthematous
pustulosis (AGEP) was made, and treatment started
with 25 mg of oral diphenhydramine every 4 hours
and triamcinolone 0.1% cream twice daily. During
day 2 of her hospitalization, she was admitted to the
critical care service for hypotension and tachycardia
that was not responsive to 5 L of intravenous normal2352-5126
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Fig 1. AGEP. Diffuse erythematous eruption covered with several hundred superficial,
nonfollicular pustules. Patient reported burning of the skin. Note confluence of pustules into
lakes of pus.
Fig 2. Accentuation in the skin folds including the waistline, intergluteal cleft, and popliteal
fossae.
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Fig 3. Biopsy specimens reveal typical histologic features of acute generalized exanthematous
pustulosis. Note subcorneal pustules with neutrophils and perivascular mixed inflammatory
infiltrate. (Hematoxylin-eosin stain; original magnifications: 34 [top], 310 [middle], 320
[bottom].)
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fluid resuscitation continued. Overnight her blood
pressure recovered, and the tachycardia resolved
with additional intravenous fluids. The lines were
removed, and she was transferred to the care of
family medicine before discharge on day 3. She
made a complete recovery without any sequela. Her
pregnancy was electively terminated.
DISCUSSION
AGEP, previously known as toxic pustuloderma,1
or generalized pustular drug rash,2 is an acute
febrile eruption that is nearly indistinguishable
clinically from pustular psoriasis but often has
distinct histopathologic features. The following 5
criteria have been proposed for the definition of
AGEP: (1) dozens of small mostly nonfollicular
pustules arising on widespread edematous ery-
thema; (2) histopathologic changes showing intra-
epidermal or subcorneal pustules associated with 1
or more of dermal edema, vasculitis, perivascular
eosinophils, or focal necrosis of keratinocytes; (3)fever ([388C); (4) neutrophilia; and (5) acute evo-
lution with spontaneous resolution in less than
15 days.3
In nearly 90% of cases, AGEP is drug induced.3
The remainder of cases are thought to be
precipitated by acute infections with enteroviruses
or by hypersensitivity to mercury.3 Beta-lactam and
macrolide antibiotics are most commonly associated
with AGEP,4 but increasing familiarity with this
clinical entity has led to the implication of an
extensive list of medications.
Treatment is generally conservative and in-
cludes stopping the responsible medication and
treating the associated symptoms. It is important to
note that the pustules are sterile, and therefore,
systemic antibiotics are unnecessary. Presentation
with fever, leukocytosis, and pustules is easily
mistaken for infection and may lead to adminis-
tration of unnecessary and potentially contraindi-
cated antibiotics.5 The lesions generally last 1 to
2 weeks, and their resolution is followed by
superficial desquamation.
Fig 4. Brisk perivascular infiltrate with many eosinophils and focal small-vessel vasculitis.
(Hematoxylin-eosin stain; original magnifications: 320 [top], 340 [bottom].)
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psoriasis. Some controversy exists about whether
these are distinct entities. In most cases, AGEP has a
more acute course of fever and pustulosis with rapid
spontaneous healing.6 The histopathology of AGEP
typically shows spongiform subcorneal and/or
intraepidermal pustules, marked edema of the
papillary dermis, possible vasculitis, eosinophils,
and/or focal necrosis of keratinocytes.5 In contrast,
pustular psoriasis more frequently has papillo-
matosis and acanthosis.5 Not surprisingly, both
demonstrate subcorneal and/or intraepidermal
pustules. In this case, a brisk perivascular dermal
infiltrate with numerous eosinophils helped to
distinguish AGEP from pustular psoriasis.
Drug reaction with eosinophilia and systemic
symptoms may also show papular and pustular
lesions. This case was differentiated from drug
reaction with eosinophilia and systemic symptoms
by lack of eosinophilia and lack of visceral
involvement (eg, hepatitis, nephritis, myocarditis,
or pneumonitis), and the rapidity of rash onset and
subsequent resolution.7 Additional consideration
was given to impetigo herpetiformis or pustular
psoriasis of pregnancy. In 1872, von Hebra8
introduced the term ‘‘impetigo herpetiformis’’ to
describe 5 cases of acute pustular eruptions in
pregnant or puerperal women. Although there is
debate surrounding its classification, this entity is
usually characterized by an eruption in the third
trimester, and is histologically consistent with
pustular psoriasis.9 Of interest, pustular psoriasis
of pregnancy may be accompanied by majorcomplications such as sepsis, placental insuffi-
ciency, and fetal morbidity and mortality.10
We believe that the acute pustular eruption in this
patient developed from the use of mifepristone.
Mifepristone, also known as RU-486 and marketed
under the trade names Korlym and Mifeprex, is
synthetic steroidal antiprogesterone. It is used as an
abortifacient in the first months of pregnancy and as
emergency contraceptive in lower doses. A prior
sensitization to mifepristone in our patient, suggest-
ing immunologic recall phenomenon, likely explains
the short interval between drug administration and
the onset of her eruption. The Naranjo Scale is a
questionnaire designed by Naranjo et al11 for deter-
mining whether a suspected adverse drug reaction is
a result of the drug or other factors. Application of
the Naranjo Scale to determine the likelihood of
adverse drug reaction revealed that mifepristone
yields a score of 5, suggesting a probable association.
As a consequence, we propose that mifepristone be
added to the list of drugs that may cause AGEP.
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